FDA Advisers Narrowly Okay Empagliflozin CV Mortality Claim

The FDA advisory committee applauded the reduction in CV deaths with this type 2 diabetes drug in the EMPA-REG OUTCOME trial but questioned supposed benefits for heart failure and renal protection.
Medscape Medical News